Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Revotar Biopharmaceuticals AG
- Target Recruit Count
- 60
- Registration Number
- NCT01108913
- Locations
- 🇩🇪
Insaf - Respiratory Research Institute GmbH, Wiesbaden, Germany
Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- Revotar Biopharmaceuticals AG
- Target Recruit Count
- 18
- Registration Number
- NCT00962481
- Locations
- 🇩🇪
Pneumologisches Forschungsinstitut GmbH am Krankenhaus Großhansdorf, Großhansdorf, Germany
Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Revotar Biopharmaceuticals AG
- Target Recruit Count
- 107
- Registration Number
- NCT00823693
- Locations
- 🇩🇪
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath